Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

Novavax Inc. closed 60.53% below its 52-week high of $17.81, which the company reached on July 26th.

Novavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental ...

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novavax Inc. closed 61.03% short of its 52-week high of $17.81, which the company achieved on July 26th.

The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.

Novavax, Inc. (Nasdaq: NVAX) today announced results of the initial cohort of its COVID-19-Influenza Combination (CIC) and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza (tNIV ...

The RSV shot, mRESVIA, secured U.S. approval on Thursday for expanded use in at-risk adults aged 18 to 59 years, but needs ...

Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in ...